Covington Reps Forest Labs In $1.2B Clinical Data Deal

Law360, New York (February 22, 2011, 2:12 PM EST) -- Forest Laboratories Inc. announced Tuesday that it would purchase Clinical Data Inc. for $1.2 billion, aiming to add Clinical Data's newly approved drug Viibryd to its portfolio of blockbuster antidepressants.

New York-based Forest, which makes antidepressants Lexapro and Celexa, is proposing to pay Clinical Data $30 in cash per share to buy up all outstanding shares of its common stock, along with contingent consideration of up to an additional $6 per share that will be paid when and if Viibryd's net U.S. sales meet or exceed...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.